Skip to content
OpenCapital
Get started

Replimune Group REPL Proceeds from maturities of short-term investments

Proceeds from maturities of short-term investments at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's proceeds from maturities of short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's proceeds from maturities of short-term investments?
Replimune Group (REPL) reported proceeds from maturities of short-term investments of $101.77M in Q4 2025.
How has Replimune Group's proceeds from maturities of short-term investments changed year-over-year?
Replimune Group's proceeds from maturities of short-term investments increased by 10.0% year-over-year, from $92.5M to $101.77M.
What is the long-term trend for Replimune Group's proceeds from maturities of short-term investments?
Over 3 years (2022 to 2025), Replimune Group's proceeds from maturities of short-term investments has grown at a 14.7% compound annual growth rate (CAGR), from $256.25M to $386.48M.